The Case for Increased Funding of Comparative Effectiveness Research
|
|
|
| Posted
:
Tue, 10 Nov 2009 13:08:31 GMT |
| Author
:
MarketResearch.com |
| Category
:
Press Release |
| News Alerts by
Email ( click
here ) |
| Press Release
News |
Home
|
|
|
|
ROCKVILLE, MD -- 11/10/09 --
MarketResearch.com has announced the addition
of GlobalData's new report "The US Government's Financial Support to Push
Comparative Effectiveness Research," to their collection of Healthcare
market reports. For more information, visit
http://www.marketresearch.com/redirect.asp?progid=67618&productid=2474912
Summary
GlobalData's new report, "The US Government's Financial Support to Push
Comparative Effectiveness Research," explores the US medical equipment
industry and the intricacies of the economic stimulus bill. The US Congress
in the early part of 2009 made available $1.1 billion in funds for
comparative effectiveness research as part of its economic stimulus
program. The main goal of comparative effectiveness research is to bring
down the costs of drugs, devices and treatments and make them available to
all the patients. Comparative effectiveness research provides relative
positives and negatives of different treatment options for the same disease
condition. Such research provides physicians and patients with information
on which to base their clinical decisions.
The healthcare industry and patients alike contend that cost alone
shouldn't be the only criteria in deciding the treatment options for
patients. Research may help save costs in the short term but eventually in
the long run the costs are going to escalate further as patients do not
receive the right treatment for their medical condition. Decisions should
be based on overall effectiveness of a drug, device or treatment rather
than on cost alone. Imposition of cost constraints may lead to worse
patients' conditions and more importantly increases the healthcare costs in
the long term.
Comparative effectiveness research needs to expand its focus to studies
that encompass all aspects of the health care delivery system rather than
just concentrating on drugs, biologics and devices. The research should
include preventative services, emergency response and diagnostic tests to
reflect the various components of the overall healthcare delivery system.
Scope
-- Insights into the medical equipment industry in the US
-- Analysis of government initiatives and incentives such as economic
stimulus program as part of the healthcare reforms
-- Review of key factors of the economic stimulus package and the
effect on the US medical equipment industry
Reasons to buy
-- Develop business strategies with the help of specific insights from
GlobalData on key events within the medical equipment industry.
-- Gain a strong understanding and analyze goverment initiatives in
the US medical equipment industry
-- Identify growth opportunities and possible challenges expected to
emergy within the medical equipment industry in the US due to the
government financial reforms
Topics covered in the report include...
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 GlobalData Viewpoint
2.1 Summary
3 The US Government's Financial Support to Push Comparative Effectiveness
Research
3.1 The US Congress to Provide $1.1 billion To Assess the
Comparative Effectiveness of Diagnosis, Treatment and Strategies
3.1.1 Agency for Healthcare Research and Quality to Spend $300 m on
Research Related to Medical Interventions
3.1.2 National Institute of Health to Spend $400 m on Scientific
Research and Development
3.1.3 Office of the Secretary of Health and Human Services to Spend
$400 m to Compliment AHRQ and NIH
3.2 Controlling Healthcare Costs is the Rationale behind Comparative
Effectiveness Research
3.3 Healthcare Industry's Concerns on Comparative Effectiveness
Research
3.4 Patients Suggestions on Implementation of Comparative
Effectiveness Research
4 Appendix
4.1 GlobalData Research Methodology
4.2 Secondary Research
4.3 Primary Research
4.4 Models
4.5 Forecasts
4.6 Expert Panel Validation
4.7 Currency Conversion
4.8 Contact Us
4.9 Disclaimer
1.1 List of Tables
Table 1: Growth in Percent of Population Over the Age of 65 Years
Table 2: USD to Local Currency, Average Exchange Rate 2008
1.2 List of Figures
Figure 1: Health Expenditures, By Expenditure Type (%), US, 2007
Figure 2: GlobalData Methodology
For more information, visit
http://www.marketresearch.com/redirect.asp?progid=67618&productid=2474912
Contact:
Gregg Kellett
MarketResearch.com
gkellett@marketresearch.com
240.747.3008
|

Copyright © 2008
Market Wire. All
rights reserved.
|
|
|
|
|
Related
News
Reportlinker Adds Baby Toiletries - A World Market Review
NEW YORK, Nov. 23 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.
Baby Toiletries - A World Market Review
Reportlinker Adds Biofuels Markets and Technologies
NEW YORK, Nov. 23 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.
Biofuels Markets and Technologies
Pro-Lifers Will Honor Jim Pouillon November 24
WASHINGTON, Nov. 23 /PRNewswire-USNewswire/ -- Pro-life advocates from the DC area will honor fallen pro-lifer, Jim Pouillon, by witnessing the evil of child-killing at 6 high schools in 4 cities on November 24. They will stand in front of the schools while the students and staff arrive, ho...
JCPenney Extends “Cyber Monday” to Two-Day Online Sale PLANO, Texas -
J. C. Penney Company, Inc. (NYSE:JCP) today announced that it will offer
its Cyber Monday online specials an entire day earlier this year, making
Sunday, Nov. 29 to Monday, Nov. 30 JCPenney’s Biggest Cyber Sale in
Company history. The two-day online sale will feature spe
Research and Markets: 2009 Analysis - Plastic Card Systems - A Comprehensive Profile Of 72 Companies Operating In the UK Market Rates Each Company on Their Acquisition Attractiveness DUBLIN -
Research and Markets (
ConvergEx Acquires Boutique Prime Brokerage Business
NEW YORK, Nov. 23 /PRNewswire/ -- ConvergEx, a leading provider of investment and execution technology solutions to institutional clients worldwide, today announced that it has signed a definitive agreement to acquire NorthPoint Trading Partners, LLC. With this acquisition, ConvergEx ...
BioAlliance Pharma Presents Efficacy and Safety Preclinical Results for Its AMEP™ Anti-Invasive Biotherapy at The ESGCT Annual Congress in Hannover, November 21 to 25, 2009 PARIS -
Regulatory news:
BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment
and supportive care of cancer and AIDS patients, has presented
preclinical results on its new biotherapy, AMEP™ for advanced and
metastatic melanoma at the ESGCT (Eur
|
|
|
|
|
|
|
|
|